Meeder Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Meeder Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-496	Closed	-$7K	–	2045
2020 Q3	$7K	Sell	496 -585	-54%	-$11K	﹤0.01%	1477
2020 Q2	$28K	Buy	1,081 +983	+1,003%	+$20.5K	﹤0.01%	1053
2020 Q1	$1K	Buy	+98	New	+$1.53K	﹤0.01%	2198
2018 Q4	–	Sell	-45	Closed	-$1K	–	1753
2018 Q3	$1K	Buy	+45	New	+$875	﹤0.01%	1479

Other funds holding KNSA

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Meeder Asset Management's KNSA Position: Q4 2020 in Review

Meeder Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2020, closing a stake of 496 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in KNSA in Q3 2018 and held it in 4 quarters. The position peaked at $28K in Q2 2020. 108 funds tracked by Wall St. Rank hold KNSA as of Q4 2020.

Meeder Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Meeder Asset Management sold 496 Kiniksa Pharmaceuticals shares in Q4 2020, an estimated $7K.
Meeder Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Meeder Asset Management's Kiniksa Pharmaceuticals position peaked at $28K in Q2 2020.
108 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.